Potency measurements of the complement system facilitated by antibodies targeting the zymogen form of complement factor D (Adipsin).


Journal

Molecular immunology
ISSN: 1872-9142
Titre abrégé: Mol Immunol
Pays: England
ID NLM: 7905289

Informations de publication

Date de publication:
06 2022
Historique:
received: 11 02 2022
revised: 18 03 2022
accepted: 05 04 2022
pubmed: 17 4 2022
medline: 18 5 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

The serine protease complement factor D is fundamental in the activation of the complement system. In addition, it was the first adipokine described (named Adipsin) and shown to improve beta cell function in diabetes. As part of an amplification loop of complement activation, factor D is a rate-limiting enzyme, and its accessibility contributes to the potency of complement activation. The dogma has been that conversion of the zymogen form, profactor D, to mature factor D occurred during secretion by adipocytes by uncharacterized proteases. However, recent findings demonstrated that the serine protease MASP-3 of the lectin pathway of the complement system mediated this conversion, suggesting that pattern recognition of pathogen/danger-associated molecular patterns could be a prior requirement for all complement activation. To facilitate studies addressing this hypothesis, we have developed monoclonal antibodies specific for human profactor D without binding to mature factor D. We demonstrate their applications in accessing the conversion of profactor D into mature factor D and in measuring levels of profactor D.

Identifiants

pubmed: 35429907
pii: S0161-5890(22)00182-1
doi: 10.1016/j.molimm.2022.04.002
pii:
doi:

Substances chimiques

Antibodies 0
Enzyme Precursors 0
Complement System Proteins 9007-36-7
Mannose-Binding Protein-Associated Serine Proteases EC 3.4.21.-
Complement Factor D EC 3.4.21.46

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-49

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Yaseelan Palarasah (Y)

Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Anne Sofie Løgstrup Henriksen (ASL)

Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Steffen Thiel (S)

Department of Biomedicine, University of Aarhus, Aarhus, Denmark.

Maiken Henriksen (M)

Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Søren W K Hansen (SWK)

Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Electronic address: shansen@health.sdu.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH